Related Experiment Videos
Didanosine once daily: an overview
1Royal Free Centre for HIV Medicine, Royal Free Hospital, Hampstead, London, UK. myoule@rfh1.demon.co.uk
Antiviral Therapy
|March 21, 2000
Summary
Once-daily didanosine (DDI) simplifies human immunodeficiency virus (HIV) treatment. This dosing strategy shows similar efficacy to twice-daily regimens with fewer toxic effects, supporting its use in HIV therapy.
Area of Science:
- Antiviral drug development
- Pharmacokinetics and pharmacodynamics
- HIV/AIDS treatment strategies
Background:
- Simplifying treatment regimens is a key goal in managing human immunodeficiency virus (HIV) infection.
- Once-daily dosing offers potential benefits for patient adherence and convenience.
Purpose of the Study:
- To evaluate the efficacy and safety of once-daily didanosine (2',3'-dideoxyinosine or DDI) therapy for HIV infection.
- To compare once-daily DDI dosing with traditional twice-daily regimens.
Main Methods:
- Review of early clinical studies investigating once-daily versus twice-daily didanosine dosing.
- Analysis of surrogate markers and toxic effects in patients receiving different DDI schedules.
- Summary of trial results for once-daily didanosine in combination therapy.
Main Results:
- Changes in surrogate markers were comparable between once-daily and twice-daily didanosine dosing.
- Toxic effects were less frequent with the once-daily dosing schedule.
- Combination therapy including once-daily didanosine has been explored in clinical trials.
Conclusions:
- Once-daily didanosine (DDI) is a viable option for simplifying HIV treatment regimens.
- This dosing schedule demonstrates comparable efficacy to twice-daily dosing with an improved safety profile.
- Further research supports the use of once-daily DDI in combination with other antiretroviral agents.